The small intestine is involved in chronic inflammation in obese people
19.06.2015 - Press release
Researchers from the French National Centre for Scientific Research (CNRS), Inserm, Pierre and Marie Curie University (UPMC) and Paris Descartes University, in collaboration with clinician researchers from the Paris Public Hospitals (AP-HP), have just shown that severe obesity is accompanied by inflammation ...
A new therapeutic approach for rare and serious kidney diseases
18.06.2015 - Press release
A team at the Paris Cardiovascular Research Centre (PARCC) (Paris Descartes University / Inserm / AP-HP) proposes a new approach for the treatment of serious kidney diseases. ...
IRF5, a new player in the occurrence of obesity complications
05.05.2015 - Press release
Teams led by Nicolas Venteclef, Dominique Langin, Karine Clément and Irina Udalova (Kennedy Institute of Rheumatology, University of Oxford, UK) in collaboration with several teams, have succeeded in elucidating part of the mechanisms involved in the development of metabolic complications associated with ...
Type 2 diabetes: understanding regulation of sugar levels for better treatment
20.04.2015 - Press release
Joint research units 1190, “Translational Research for Diabetes,” directed by François Pattou, and 1011 “Nuclear Receptors, Cardiovascular Diseases and Diabetes,” directed by Bart Staels, describe a new mechanism that controls glucagon secretion in humans, making it possible to elucidate this phenomenon and ...
Antiplatelet agents help reduce the severity of flu
02.04.2015 - Press release
Platelets play a role in severe lung infections associated with flu viruses. This has been highlighted for the first time by a team of researchers from France's National Institute for Agricultural Research (Inra), National Institute for Health and Medical Research (Inserm) and ...
Targeting a host receptor instead of the virus: a new experimental approach against hepatitis C virus.
24.03.2015 - Press release
(Français) Une collaboration internationale conduite par le Professeur Thomas Baumert met en évidence qu’un anticorps monoclonal spécifiquement dirigé contre la claudine-1, permet de prévenir et de traiter une infection chronique par ce virus dans un modèle animal. ...